BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Taiho Pharmaceutical Company Ltd. 

1-27 Kandanishiki-cho

Chiyoda-ku  Tokyo  101-8444  Japan
Phone: N/A Fax:


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical






 Company News
Taiho Pharmaceutical's Lonsurf® (Trifluridine And Tipiracil Hydrochloride) Tablets Approved In Japan For Treatment Of Advanced Metastatic Colorectal Cancer 3/24/2014 6:32:25 AM    More...
Response Genetics, Inc. Renews Agreement With Taiho Pharmaceutical to Provide Molecular Analyses for Cancer 7/17/2013 9:28:54 AM    More...
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102 2/27/2013 9:32:07 AM    More...
Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102 5/31/2012 12:28:08 PM    More...
Taiho Pharmaceutical Announces Results of Randomized Phase II Clinical Trial with Novel Antitumor Agent TAS-102 7/22/2011 6:15:40 AM    More...
Taiho Pharmaceutical's Teysuno(TM) (S-1) Receives European Marketing Authorization as First-Line Therapy for Advanced Gastric Cancer 3/15/2011 8:17:44 AM    More...
Taiho Pharmaceutical: Teysuno(TM) (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer 12/17/2010 6:41:43 AM    More...
Taiho Pharmaceutical Selects Medidata Solutions, Inc. Rave for Global Trials 7/28/2008 9:04:18 AM    More...
Taiho Pharmaceutical and Sanofi-Aventis (France) (SASY.PA) Release: S-1, a Novel Oral Fluoropyrimidine, When Combined With Cisplatin, Demonstrates Significant Improvement in Overall Survival of Advanced Gastric Cancer Patients Over S-1 Alone 6/4/2007 2:47:24 PM    More...
Makoto Life Sciences, Inc. Signs $20 Million Research Collaboration With Taiho Pharmaceutical 8/2/2006 5:03:18 PM    More...
123